Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
3,734 total articles
Juel Carol, Executive Vice President and Chief Technology and Operating Officer at Synchrony Financial (NYSE:SYF), executed an open-market sale of 16,859 shares on March 2, 2026 for about $1.14 million and, a day earlier, received a grant of 24,093 restricted stock units valued at $1,665,067. Tax withholding of 14,561 shares reduced the net impact …
Netflix director Reed Hastings completed the sale of 410,650 common shares on March 2, 2026, generating about $39.8 million through multiple trades priced between $96.0572 and $97.5869. On the same day he exercised options to buy 410,550 shares at $9.667 each. Following these moves, Hastings holds a small direct stake and a substantial indirect pos…
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported an insider sale by Executive Vice President and Chief Quality Operations Officer John Richard Pinion, who sold 10,029 shares on March 2, 2026, for roughly $228,661. The transaction followed the conversion of performance stock units into common shares the prior day and leaves Pinion with 110,026…
Trupanion Chief Operating Officer John R. Gallagher sold 5,283 shares on February 27, 2026, for about $140,080 under a pre-arranged Rule 10b5-1 plan. The stock trades near a 52-week low after a six-month decline. The company reported fourth-quarter 2025 results that beat revenue estimates but missed on earnings per share, and InvestingPro analysis …
Neville Everett, an officer at Cigna Group (CI), sold 1,719 shares on March 2, 2026, under a Rule 10b5-1 plan adopted May 22, 2025, for $288.91 per share, totaling $496,636. Separately, on February 27, 2026, Everett completed several other equity-related actions including zero-value acquisitions, tax-related dispositions, and the grant of options t…
Elizabeth C. Cushman, Abbott Laboratories' Executive Vice President, General Counsel and Secretary, completed two sales of Abbott common stock in late February and early March 2026 totaling $195,602. After the transactions she holds 38,573 shares. Abbott continues to declare dividends, report positive clinical outcomes for an atrial fibrillation th…
Robert P. Goodman, a director at CS Disco, Inc. (NASDAQ: LAW), purchased 1,026,700 shares on February 27, 2026, in a transaction valued at $3,275,173. The purchase occurred at prices between $3.10 and $3.19. Following the trade, Goodman’s direct and indirect holdings are disclosed. CS Disco recently reported fourth-quarter 2025 results that beat an…
Reddit CEO Steve Huffman sold 17,900 shares of Class A common stock on February 27, 2026, in multiple trades totaling about $2.6 million. The trades were carried out under a pre-arranged Rule 10b5-1 plan adopted May 19, 2025. On the same day Huffman exercised options to acquire 18,000 Class A shares at a price of $0.00 per share; those options were…
Atomera Inc. (NASDAQ: ATOM) Chief Technology Officer Robert J. Mears sold 3,989 shares on March 2, 2026, while simultaneously receiving substantial equity awards at no cost. The move coincides with the company’s recent registered direct offering, a fourth-quarter 2025 earnings report that met EPS expectations but showed weak revenue, and share-pric…
Atomera Inc.'s chief financial officer, Francis Laurencio, sold 4,799 shares on March 2, 2026, for $4.95 per share, generating $23,755 in proceeds. The transaction coincided with the stock trading below its prior close, despite the equity being up 117% year-to-date. A Form 4 filing also shows Laurencio received 114,504 shares through performance an…
Acumen Pharmaceuticals Chief Legal Officer Derek M. Meisner sold 9,406 shares of common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 plan and exercised options to buy the same number of shares the same day. The sale generated about $28,311 at a weighted average price of $3.0099, while the option exercise paid $1.85 per share for a to…
Mark A. Goldsmith, a director at Revolution Medicines (RVMD), sold common shares totaling $3,644,353 on March 2, 2026, and executed option activity across March 1-2. The company recently reported a wider fourth-quarter 2025 loss driven by higher R&D and SG&A spend, while several analysts revised coverage and price targets.
Arlo Technologies' Chief Financial Officer, Kurtis Joseph Binder, sold 12,539 shares on March 3, 2026, realizing $187,183 at a weighted average price of $14.9281. The transaction, disclosed on a Form 4 filed with the SEC, reduced Binder's direct holdings to 470,635 shares. The sale occurred after the stock climbed 27% during the prior week and ahea…
Arlo Technologies CEO Matthew Blake Mcrae sold 27,931 shares on March 3, 2026, for about $416,959 to cover estimated taxes related to restricted stock units. The transaction occurred at a weighted average price of $14.9282. The firm posted fourth-quarter 2025 earnings and revenue above analyst forecasts, yet InvestingPro flags the stock as overvalu…
EverCommerce Inc. Chief Executive Officer Eric Richard Remer disposed of 19,200 shares of common stock on March 3, 2026, in a transaction recorded on an amended Form 4/A with the SEC. The sale, conducted under a Rule 10b5-1 plan established in mid-2025, generated $219,363 at a weighted average price of $11.4252. Separately, analysts have recently a…
Nicole S. Jones, an executive at Cigna Group (CI), sold 2,307 shares on March 2, 2026 under a Rule 10b5-1 plan, generating $666,515. The transactions follow earlier February sales and coincide with equity vesting, option grants and a strong fourth-quarter 2025 earnings report. The company also disclosed a planned CEO transition effective July 1, 20…
Nathan B. Theurer, First Solar's vice president - global controller and CAO, reported the sale of 49 shares on March 3, 2026, for roughly $9,600. The filing also shows a vesting of performance share units earlier in the week and leaves Theurer with 92 directly held shares. The disclosure arrives amid a string of analyst adjustments following First …
AirJoule Technologies Corp. (NASDAQ: AIRJ) Chief Administrative Officer Jeff Gutke disposed of 3,462 Class A shares on March 3, 2026, to satisfy tax withholding obligations connected to recent restricted stock unit vesting. The trade, reported on a Form 4, was non-discretionary. The company has also priced a public offering to raise roughly $20 mil…
Alta Equipment Group INC Chief Financial Officer Anthony Colucci sold 8,137 shares of common stock on March 3, 2026, for about $57,379 at an average price of $7.0517 per share. Earlier, Colucci received equity from performance stock units and restricted stock units on February 27, 2026. Alta also disclosed fourth-quarter 2025 results that topped es…
Alta Equipment Group Inc. Chief Executive Officer Ryan Greenawalt sold 27,986 shares on March 3, 2026, for about $197,290 at a weighted average price of $7.0496. The disposition follows a February 27 grant of performance stock units and restricted stock units and comes amid a 58% year-to-date stock rally. Alta reported Q4 2025 results that beat exp…
DraftKings Chief Accounting Officer Erik Bradbury sold 2,883 shares of Class A stock on March 3, 2026, for about $70,800 in multiple trades. The company is trading near a 52-week low even as several brokerages reiterated positive ratings tied to an upcoming integrated app and expanded market forecasts. Bradbury also received shares through recent r…
Barrett Business Services Inc (NASDAQ: BBSI) director Mark Steven Finn acquired 2,000 shares of company stock in early March, investing $55,315 across two trades recorded on a Form 4 with the SEC. The purchases come amid a recent pullback in the stock and a quarterly report that showed small EPS growth and revenue gains that fell short of analyst e…
Jeff B. Gustavson, President of New Energies at Chevron Corp (CVX), sold 6,667 shares of company stock on February 27, 2026, for $1,240,324 at $186.0394 per share and on the same day exercised options to acquire 6,667 shares at $125.35 each, valued at $835,708. The transactions occurred as Chevron traded near its 52-week high and against a backdrop…
Krystal Biotech director Daniel Janney sold 11,803 shares of common stock on February 27, 2026, in two transactions executed under a Rule 10b5-1 trading plan, generating $3.25 million. The company recently reported fourth-quarter 2025 results that exceeded analyst estimates for both earnings per share and revenue. Krystal shares have advanced mater…
Docusign director James A. Beer sold 450 shares on March 3, 2026, for $45.02 each, totaling $20,259. The company has announced AI-driven product integrations and features, and an analyst reiterated an outperform rating with a $124 price target. Company shares have partially rebounded in the last week but remain well below six-month levels.
